Pioneering the industrialisation of precision medicines
Matt Todd, Head of Architecture, Ori Biotech
Cell and gene therapies (CGT) have proven effective, yet only a very small portion of patients are able to access treatments, typically as third- or fourth-line treatments. Ori Biotech are leading manufacturing technology company building a CGT manufacturing platform to enable widespread access to these life-changing treatments.
However, this requires urgent modernization of the legacy and manual technologies used during therapy development and manufacturing. These outdated technologies are having a dramatically negative effect on scalability, resulting in extremely limited manufacturing slots and very high cost of goods-resulting in patients dying whilst on waitlists for CGT.
Join this session to understand how other industries have solved these challenges through digital transformation and automation, and how their learnings can be applied to CGT to enable the industrialisation of patient-specific therapies. You will also gain insights into how Ori Biotech is tackling digitalisation in the CGT space.